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Background: Inattentiveness, impulsivity and hyperactivity are the primary behaviors associated with
attention-deficit hyperactivity disorder (ADHD). Previous studies showed that peripheral blood gene expression
signatures can mirror central nervous system disease. Tourette syndrome (TS) is associated with inattention (IA) and
hyperactivity/impulsivity (HI) symptoms over 50% of the time. This study determined if gene expression in blood
correlated significantly with IA and/or HI rating scale scores in participants with TS.
Methods: RNA was isolated from the blood of 21 participants with TS, and gene expression measured on
Affymetrix human U133 Plus 2.0 arrays. To identify the genes that correlated with Conners’ Parents Ratings of IA
and HI ratings of symptoms, an analysis of covariance (ANCOVA) was performed, controlling for age, gender and
batch.
Results: There were 1201 gene probesets that correlated with IA scales, 1625 that correlated with HI scales, and
262 that correlated with both IA and HI scale scores (P<0.05, |Partial correlation (rp)|>0.4). Immune, catecholamine
and other neurotransmitter pathways were associated with IA and HI behaviors. A number of the identified genes
(n=27) have previously been reported in ADHD genetic studies. Many more genes correlated with either IA or HI
scales alone compared to those that correlated with both IA and HI scales.
Conclusions: These findings support the concept that the pathophysiology of ADHD and/or its subtypes in TS may
involve the interaction of multiple genes. These preliminary data also suggest gene expression may be useful for
studying IA and HI symptoms that relate to ADHD in TS and perhaps non-TS participants. These results will need to
be confirmed in future studies.
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Inattentiveness, impulsivity and hyperactivity are com-
mon behaviors seen in children. When pronounced,
these behaviors may lead to the diagnosis of attention-
deficit hyperactivity disorder (ADHD) [1]. ADHD is
among the most common of the childhood onset psychi-
atric disorders [2,3]. Clinically, children with ADHD may* Correspondence: tianyf18@gmail.com
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reproduction in any medium, provided the orbe diagnosed as predominantly inattentive type, predom-
inantly hyperactive/impulsive type or combined type
characterized by both inattention (IA) and hyperactivity/
impulsivity (HI) behaviors [3,4]. The difference between
the subtypes is based mainly on clinical profiles [4].
Tourette syndrome (TS), characterized by motor and
vocal tics, is often associated with ADHD symptoms. TS
is a heritable, complex genetic disorder where multiple
genes, each with a modest effect, are postulated to inter-
act with unknown environmental factors to produce the
phenotype [5,6]. Patients with TS often display comorbid
symptoms of ADHD. Of subjects with TS who visit a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rate that is 10 to 20 times that of the general population
[5]. In our previous study, a subgroup of patients with TS
over-expressed natural killer cell genes in blood, and
most of these patients with TS had co-morbid ADHD
[7]. These findings stimulated the current study to fur-
ther examine the relationship of gene expression in blood
of patients with TS that also exhibit ADHD behaviors.
Recent studies suggest that ADHD symptoms might
best be considered as continuous quantitative traits ra-
ther than diagnostic categories [1]. This has arisen in
part because candidate gene and genetic linkage studies
of the ADHD subtypes have shown conflicting results
[1,4]. Therefore, this study of gene expression considers
inattention and hyperactivity/impulsivity as continuous
variables without regard to the categorical clinical diag-
noses of ADHD subtypes. Examining these behaviors in
participants with TS might provide more homogeneous
phenotypes since TS is highly heritable, and is readily
and objectively identifiable. Cytogenetic, linkage and
GWAS analyses have uncovered a number of loci and
several genetic mutations that are associated with Tour-
ette syndrome. For example, mutation in SLIT and
NTRK-like 1 (SLITRK1) can cause TS, and though there
are other examples, each only accounts for a small frac-
tion of cases [8,9] Notably, our previous study discov-
ered a set of specific alternatively spliced genes that
differentiate TS from controls, suggesting that there may
be a shared molecular pathophysiology common to
many subjects with TS [10].
Thus, the current study quantified IA and HI beha-
viors using the Conners’ Parent Rating Scales-Revised
(CPRS-R) in a group of participants with TS. The well-
validated Conners’ scale is widely used in research and
clinical practice to diagnose ADHD and evaluate treat-
ment effects in the disorder [3]. Gene expression was
quantified using Affymetrix U133 Plus 2.0 arrays and
correlated with the IA and HI scores from the CPRS in
the same subjects. Gene expression was measured in
whole blood because of its accessibility and because of
known interactions between the immune system and the
central nervous system [7,10-12].
Methods
Participants
All participants with TS were recruited via the Tourette
Syndrome Association, clinical referrals, local advertise-
ments, physician referrals, and through the University of
California at Davis. The participants were recruited as
part of a functional magnetic resonance imaging study
of tic severity and cognitive control conducted by Dr. S.
Bunge and colleagues [13]. All of the participants with
TS were diagnosed based on DSM-IV-TR criteria. Tic
severity was assessed based on direct child and parentinterview using the Yale Global Tic Severity Scale
(YGTSS). The CPRS-R was used to assess ADHD symp-
toms using continuous, standardized age and gender
adjusted CPRS-t scores. The parent ratings are useful
and valid as they have the opportunity to observe their
children over extended periods of time and in a variety
of situations. The scale contains 27 items and is com-
posed of 4 subscales including: Cognitive Problems/In-
attention, Hyperactivity, Oppositional and the ADHD
Index [3]. A major advantage of the CPRS-R is that it
uses a very large normative database (8,000+ children)
to support the validity and reliability of it. Furthermore,
the standardized data from the CPRS were derived from
the means and standard deviations for children with and
without ADHD. No clinical diagnosis of ADHD was
made in the study. Protocols were approved by the insti-
tutional review board at the University of California at
Davis. Verbal assent was obtained from each subject and
written informed consent was obtained from the parent
or legal guardian of each participant.
Sample collection and RNA isolation
Blood sample collection and RNA isolation were per-
formed as described previously [10]. Whole blood
(15ml) was collected from each subject via antecubital
fossa venipuncture into six PAXgene Vacutainer tubes
(Qiagen, Valencia, CA, USA). These tubes contain a so-
lution that immediately lyses all of the cells in whole
blood and stabilizes the RNA without measurable deg-
radation. Blood samples were stored frozen at -70°C
until processed.
Total RNA was isolated using the PAXgene Blood
RNA Kit (Qiagen) according to the manufacturer’s
protocol. RNA quality was assessed using the Agilent
2100 Bioanalyzer (Agilent Technologies Inc., Foster City,
CA, USA) and quantified using fiberoptic spectropho-
tometry (Nanodrop ND-1000, Nanodrop Inc., Wilming-
ton, DE, USA). RNA yielding both an A260/A280
absorbance ratio greater than 2.0 and a 28s/18s rRNA
ratio equal to or exceeding 1.8 was utilized.
Affymetrix human genome U133 plus 2.0 Microarray
processing
Human Genome U133 Plus 2.0 microarray processing
was performed according to the manufacturer’s proto-
col. The Ovation RNA Amplification System V2 kit and
the OvationW WB Reagent kit (NuGEN, San Carlos,
CA) were used to optimize whole blood amplification
starting with 50 ng total RNA, the amplified cDNA was
fragmented and labeled using NuGEN’s FL-Ovation™
cDNA Biotin Module V2 (NuGEN, San Carlos, CA).
Hybridization, washing and scanning were performed
according to the Affymetrix Human U133 Plus 2.0 pro-
tocols (Affymetrix, Santa Clara, CA).
Figure 1 Venn diagram showing total numbers of probesets
that correlated with the CPRS Inattention (IA) and
Hyperactivity/Impulsivity (HI) scales or both (P<0.05, |rp|>0.4).
Note that 262 probesets correlated with both the IA and HI scales.
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We deposited the raw data at GEO under accession
number GSE30470 and can confirm all details are
MIAME (Minimum Information About a Microarray
Experiment) compliant. Raw data (Affymetrix.CEL files)
were imported into Partek Genomics Suite 6.4 (Partek
Inc., St. Louis, MO, USA). Probe summarization and
probe-set normalization were performed using Robust
Multi-Chip Average (RMA), which included background
correction, quantile normalization, log2-transformation
and median polish probe set summarization. Principal
Components Analysis (PCA) was employed to detect
outliers because outliers can have a profound influence
on correlation coefficients.
To identify the genes that correlated with the CPRS-R
inattention or hyperactivity/impulsivity scales, an ana-
lysis of covariance (ANCOVA) was performed, control-
ling for the effects of age, gender and batch (random
effect). Of the ~54,000 probesets on the Affymetrix
U133 plus 2.0 array, about 36,000 were analyzed after fil-
tering out the probesets targeting non-annotated tran-
scripts, opening reading frames and hypothetical genes.
No probesets met the high stringency of a false-
discovery correction for multiple comparisons. Thus, we
initially considered a main effect of probesets meeting
criteria P<0.05 and |rp| >0.4, supplemented with a path-
way and network over-representation approach. Ingenu-
ity Pathways Analysis (IPA 8.0, IngenuityW Systems) was
used to identify statistically significant functional cat-
egories in the data set using a modified Fisher Exact test,
with P<0.05 considered significant. To further support
the pathway-related ADHD genes, those involved in
the significant pathways were subjected to a co-
expression analysis by first performing gene-gene cor-
relation in Partek, and then hierarchical clustering
based on gene-gene correlation coefficients by Genesis
(Gene Expression Similarity Investigation Suit) software.
Chromosome over-representation was identified using




The mean age of the 21 participants with TS in this
study was 10.5 years (SD 2.2, range 7 to 15). There were
17 males (81.9%) and 4 females (18.1%), including 15
persons identifying themselves as Caucasian (71.5%), 2
Hispanic (9.5%), and 4 as Other ethnic category (19.0%).
The mean tic severity was 23.4 (SD 8.4, range from 8 to
41). The mean HI rating score was 66.1 (SD15.7, range
from 47 to 90), and the average IA rating score was 63.1
(SD 13.8, range from 42 to 82). The HI and IA scores
had a normal distribution (Kolmogorov-Simirnov Test,
P=0.13 for HI, P=0.48 for IA). All of the participantswere medication naive as per parental reports, except for
two participants who had previously taken atomoxetine
(Strattera™; Eli Lilly, IN, USA) to treat ADHD symptoms.
One of these participants ended medication approxi-
mately 1 month before participation in the study. The
other stopped taking medication 40 hours before
participation.
Gene expression correlation analysis
The expression of 1201 probesets (representing 1074
genes) correlated with IA scores (IA-associated genes,
P<0.05 and |rp|>0.4) (Figure 1, Additional file 1: Table
S1–1). The expression of 1625 probesets (representing
1364 genes) correlated with HI scores (HI-associated
genes, P<0.05 and |rp|>0.4) (Figure 1, Additional file 1:
Table S1–2). The expression of 262 probesets (represent-
ing 250 genes) correlated with both IA and HI scores
(Common IA-HI genes, P<0.05 and |rp|>0.4) (Figure 1,
Additional file 1: Table S1–3).
Common IA-HI associated genes
The over-represented canonical pathways associated
with both IA and HI genes included IL-4, B cell receptor,
axonal guidance, T cell receptor and glucocorticoid re-
ceptor signaling (Table 1, Additional file 2: Table S2–1).
An IPA network analysis showed the common IA-HI
genes to be associated with cell death, behavior, and ner-
vous system development and function (Figure 2). The
co-expression analysis of pathway-related genes revealed
distinct patterns of gene expression relating to symp-
toms. Namely, the genes that positively correlated with
both IA and HI scales clustered together, and likewise
for the negatively correlated genes (Additional file 3:
Figure S1). The common IA-HI genes were over-
represented on chromosome 3 (Additional file 2: Table
Table 1 Over-represented canonical pathways in genes
that correlated with CPRS-R for IA, HI or both
Canonical pathways P-value
Canonical pathways associated with common IA-HI genes
IL-4 Signaling 1.10 x 10-4
B Cell Receptor Signaling 1.30 x 10-4
Axonal Guidance Signaling 9.43 x 10-4
T Cell Receptor Signaling 4.95 x 10-3
Glucocorticoid Receptor Signaling 8.09 x 10-3
Canonical pathways associated with HI-specific genes
Integrin Signaling 7.29 x 10-6
Toll-like Receptor Signaling 1.61 x 10-4
B Cell Receptor Signaling 1.77 x 10-4
Role of NFAT in Regulation of the Immune Response 2.71 x 10-4
Growth Hormone Signaling 4.71 x 10-4
Natural Killer Cell Signaling 8.54 x 10-4
Canonical pathways associated with IA-specific genes
B Cell Development 2.74 x 10-5
Antigen Presentation Pathway 4.93 x 10-3
Cardiac β-adrenergic Signaling 7.88 x 10-3
B Cell Receptor Signaling 1.02 x 10-2
Primary Immunodeficiency Signaling 1.40 x 10-2
GM-CSF Signaling 2.15 x 10-2
Figure 2 Network analysis showed cell death, behavior and
nervous system development and nervous system function as
the most over-represented network for the 262 common
Inattention/ Hyperactivity/ Impulsivity (IA-HI) probesets
(P<0.05, |rp|>0.4). Red: positively correlated genes, Green: negatively
expressed genes.
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ciated with ADHD included solute carrier family 6
(neurotransmitter transporter, noradrenalin), member 2
(SLC6A2) and glutamate receptor, ionotropic, N-methyl
D-aspartate 2B (GRIN2B) (Table 2).
HI-associated genes
The over-represented canonical pathways in HI-
associated genes included integrin, Toll-like receptor, B
cell receptor, role of nuclear factor of activated T-cells
(NFAT) in regulation of the immune response, growth
hormone and natural killer cell signaling (Table 1, Add-
itional file 2: Table S2–1). The co-expression analysis of
pathway-related genes showed separate clustering for
the genes that positively and negatively correlated with
HI (Additional file 4: Figure S2). The genes were over
represented on chromosomes 2, 3, 16, 17, and 19 (Add-
itional file 2: Table S2–2). The genes correlating with HI
included catechol-O-methyltransferase (COMT), dopa-
mine receptor D2 (DRD2), monoamine oxidase A
(MAOA), and solute carrier family 6 (neurotransmitter
transporter, serotonin), member 4 (SLC6A4) – all having
previously been associated with ADHD (Table 2).
IA-associated genes
The over-represented canonical pathways in IA-
associated genes included B cell development, antigen
presentation pathway, cardiac β-adrenergic signaling, B
cell receptor signaling, primary immunodeficiency sig-
naling and GM-CSF signaling (Table 1, Additional file 2:
Table S2–1). The co-expression analysis of pathway-
related genes showed separate clustering for the genes
that positively and negatively correlated with IA
(Additional file 5: Figure S3). The genes were over repre-
sented on Chromosomes 1, 3, 5, 12 and 13 (Additional
file 2: Table S2–2). IA-associated genes which have been
previously associated with ADHD included myelin-
associated oligodendrocyte basic protein (MOBP), dopa-
mine receptor D1 (DRD1), forkhead box P1 (FOXP1)
and fatty acid desaturase 2 (FADS2) (Table 2).
Discussion
This is one of the first studies to relate gene expression
in peripheral blood to neuropsychiatric symptoms using
whole genome expression arrays. The expression of
many genes correlated with the IA, HI scales or both.
This finding supports the concept that the pathophysi-
ology of ADHD and/or its subtypes likely involves the
interaction of multiple genes. Additionally, the genes
that correlated with both IA and HI (common IA-HI
genes) may provide a molecular correlate of the com-
bined symptoms in ADHD, as well as facilitate an under-
standing of the association between IA and HI
symptoms. Given the small number of participants, the
Table 2 Genes that correlated with IA, HI scale or both in the current study previously associated with ADHD in
published genetic studies
Gene symbol Gene title P-value (HI) rp(HI) P-value (IA) rp (IA) Reference
Common IA–HI genes
GRIN2B glutamate receptor, ionotropic,
N-methyl D-aspartate 2B
0.015 −0.54 0.043 −0.47 [14]
SLC6A2 solute carrier family 6
(neurotransmitter transporter,
noradrenalin), member 2
0.006 0.58 0.023 0.50 [15]
HI-associated genes
BCB1 ATP-binding cassette, sub-family B
(MDR/TAP), member 1
0.015 −0.44 [16]
ADAMTS2 ADAM metallopeptidase with
thrombospondin type 1 motif, 2
0.048 0.45 [6]
AR androgen receptor 0.041 0.46 [5]
ARRB2 arrestin, beta 2 0.006 0.62
COMT Catechol-O-methyltransferase 0.015 −0.58 [17]
DRD2 dopamine receptor D2 0.007 0.44 [17]
HES1 hairy and enhancer of split 1,
(Drosophila)
0.002 −0.60 [17]
LPL lipoprotein lipase 0.029 −0.52 [6]
MAOA monoamine oxidase A 0.006 −0.57 [17]
NOS1 nitric oxide synthase 1 (neuronal) 0.004 −0.62 [18]
NR4A2 nuclear receptor subfamily 4,
group A, member 2
0.009 0.53 [19]
PPM1F protein phosphatase 1F
(PP2C domain containing)
0.004 0.59 [6]
SLC6A4 solute carrier family 6 (neurotransmitter
transporter, serotonin), member 4
0.006 0.65 [17]
SULF2 sulfatase 2 0.013 0.46 [6]
TFEB transcription factor EB 0.034 0.48 [6]
CCDC136 coiled-coil domain containing 136 0.036 0.409 [20]
ATP11A ATPase, class VI, type 11A 0.018 0.511 [20]
DUSP1 dual specificity phosphatase 1 0.014 0.551 [21]
SH3BGRL2 SH3 domain binding
glutamic acid-rich protein like 2
0.001 0.697 [22]
IA-associated genes
FOXP1 forkhead box P1 0.001 −0.62 [6]
FADS2 fatty acid desaturase 2 0.011 −0.52 [23]









Rac exchange factor 2
0.007 −0.51 [20]
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subsequent studies. This study did not test whether the
genes identified could be used to distinguish individuals
with ADHD of the predominantly IA, predominantly HI,or combined types. The current study identified genes
that correlated with IA, HI scales or both across all of
the participants with TS. These genes might be useful in
identifying ADHD phenotypes but future studies with a
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How gene expression in blood might correlate with
ADHD symptoms
One of the questions this study raises is how RNA ex-
pression in peripheral blood cells might correlate with
IA or HI symptoms that are thought to be mediated by
central nervous system pathways. First, many of the neu-
rotransmitters and receptors expressed in brain are also
expressed in peripheral leukocytes [7,10-12]. Factors that
affect neurotransmitters and receptors that mediate
symptoms in brain may affect the same neurotransmit-
ters and receptors in leukocytes. Such factors that might
affect gene expression in both blood and brain and affect
IA and HI symptoms include catecholamines, stress
hormones, chemokines and cytokines. In addition, per-
ipheral leukocytes that might be involved in the patho-
genesis of TS can signal to neurons via the endothelial
cells at the blood brain barrier (BBB). For example, it
has been shown that up-regulation of choline acetyl-
transferase (ChAT) and acetylcholine (ACh) receptor
expression in T and B cells [25] can signal via the
BBB endothelial cells to neurons in brain [11], a path-
way that could modulate ADHD symptoms. Finally,
neurons in brain can signal to leukocytes in blood via
the endothelial cells at the BBB. For example, neuronal
release of catecholamines can signal to BBB endothelial
cells which can change adhesion molecule expression
on the endothelial cells that then signal to leukocytes.
These mechanisms are hypothetical since the current
studies cannot gauge what the relationship between
blood and brain gene expression might be, particularly
given the different genetic influences in blood com-
pared to brain. Though the exact mechanism is un-
known, the correlation of gene expression in blood
with IA, HI behaviors or both may provide unique
insights into pathogenesis of ADHD symptoms.
Common IA-HI associated genes
Most of the top pathways associated with the common
IA-HI genes in participants with TS were immune-
related including IL-4 Signaling, B cell receptor sig-
naling, T cell receptor signaling, and glucocorticoid
receptor signaling. Glucocorticoid release, which is
mediated by the hypothalamic-pituitary-adrenal axis,
could affect IA and HI symptoms and gene expression
of leukocytes [26]. Network analysis showed the com-
mon IA-HI genes were associated with cell death, behav-
ior, as well as nervous system development and function
(Figure 2). Imaging studies in ADHD [2,27] have sug-
gested many brain structures associated with cognitive/
attention networks display functional abnormalities.
These interacting neural regions included the dorsalanterior mid cingulate cortex, dorsolateral prefrontal
cortex, ventrolateral prefrontal cortex, parietal cortex,
striatum and cerebellum [2]. These brain network
changes could be associated at least in part with the mo-
lecular network changes noted here (Figure 2).
The neurotransmitter genes SLC6A2 and GRIN2B
observed in the common IA-HI gene list have been asso-
ciated with ADHD. SLC6A2 is a norepinephrine trans-
porter that has been studied in ADHD due to the fact
that drugs that block the norepinephrine transporter are
efficacious in treating ADHD [17,28]. SNPs in the
SLC6A2 gene have been associated with ADHD [15].
Glutamatergic signaling pathways also represented can-
didate susceptibility genes. Thus, three SNPs in the
GRIN2B gene were associated with ADHD, and quanti-
tative trait analyses showed associations of these markers
with both the IA and HI symptom dimensions of
ADHD. Disruption of GRIN1 (2A-D), another glutamate
receptor subunit gene, leads to significant alterations in
cognitive and/or locomotor behavior including impair-
ments in latent learning, spatial memory tasks and
hyperactivity [14].
HI-associated genes
One of the top canonical pathways over-represented in
HI-candidate genes was the role of NFAT in the regula-
tion of the immune response and natural killer cell sig-
naling. This is consistent with a previous report of
natural killer cell genes being differentially expressed in
TS patients diagnosed with ADHD [7]. Other HI-
candidate genes were associated with integrin and
growth hormone signaling. Recent Genome Wide Asso-
ciation Studies (GWAS) studies found that basic bio-
logical processes, especially integrin signaling, are
involved in ADHD pathophysiology [6].
The neurotransmitter-related genes COMT, DRD2,
MAOA and SLC6A4 were also included in the HI-
candidate gene list and have been previously associated
with ADHD [17,29] . DRD2, COMT and MAOA are
catecholaminergic genes. SLC6A4 is a serotonin trans-
porter that transports the neurotransmitter serotonin
from synaptic clefts into presynaptic neurons. MAOA is
a mitochondrial enzyme which degrades norepinephrine,
dopamine and serotonin [17]. COMT also catalyzes deg-
radation of catecholamines including dopamine, nor-
epinephrine and epinephrine. The DRD2 dopamine
receptors mediate the effects of dopamine in the indirect
basal ganglia pathway. The density of DRD2 receptors is
highest in the basal ganglia, and HI is related to exces-
sive dopamine activity in the basal ganglia [29,30].
IA-associated genes
Genes expressed in blood that correlated with IA symp-
toms and have been previously associated with ADHD
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most abundant in the prefrontal cortex (PFC) which is
believed to be critical for regulating attention, motiv-
ational behavior and emotion. Either too little or too
much DRD1 receptor stimulation impairs PFC function
[31]. In addition, genetic studies have suggested an asso-
ciation between DRD1 with the ADHD IA symptoms in
particular [24].
GWAS have suggested that SNPs in the FOXP1 and
MOBP genes are associated with ADHD [6]. FOXP1 is a
FOX transcription factor family member. FOX transcrip-
tion factors regulate tissue- and cell type-specific gene
transcription during both development and adulthood.
Another family member FOXP2 is involved in develop-
mental speech and language disorders and directly regu-
lates targets related to neural development and synaptic
plasticity and developmental disorders like autism and
schizophrenia [6].
Limitations
This study only addressed gene expression correlated
with the ADHD symptoms (IA and HI) in participants
with TS, and did not consider other co-morbidities like
tic severity or obsessive-compulsive symptom severity. It
is not known if the genes associated with IA and HI
symptoms in the TS subjects could be replicated in gen-
eral populations of children with ADHD. Given that
many genes overlapped between IA and HI symptoms in
subjects with TS, some of these might also overlap in
subjects with ADHD without TS.
Two participants who had been previously prescribed
medication were included in the current study. To deter-
mine if these subjects might have biased the results, our
Principal Components Analysis (not shown) revealed
that there were no outliers in the gene expression data,
suggesting these two individuals did not significantly
bias the correlations observed. Moreover, our previous
studies including these individuals did not show them to
be outliers with regard to fMRI findings or alternative
splicing [10,13]. Nevertheless, the fact that prior medica-
tions might affect blood gene expression should be
addressed in future research.
The largest limitation of the study is that, in spite of
many genes being correlated with HI and/or IA symp-
toms, no gene passed multiple comparison correction
testing using the Benjamini-Hochberg False Discovery
rate (FDR<5%), and none of the genes were confirmed
using an independent method such as RT-PCR. Thus, a
future confirmatory study likely including RT-PCR and
possibly corrections for blood cell types in a much a lar-
ger sample size will be needed to validate the genes
reported here.
Genetic studies have shown that of the many genes
involved in ADHD, a given gene may only contribute asmall percent to the symptoms [5,6,17]. This could ex-
plain the modest association between a single gene and
ADHD symptoms. Thus, pathways identified in this
study are likely to be more reproducible in follow up
studies rather than individual genes. Importantly, a gene
co-expression analysis did validate these pathway-related
ADHD genes. Moreover, our gene-gene correlation
results demonstrate that the multiple probesets targeting
a specific gene on the Affymetrix human U133 arrays
were highly correlated each other (Additional file 6 Table
S3). The validity of the findings is also supported by the
fact that 27 genes that correlated with IA and/or HI
scales have been reported in previous genetic studies of
ADHD (Table 2).
Conclusions
These findings support the concept that the pathophysi-
ology of ADHD and/or its subtypes in TS may involve
the interaction of multiple genes. Even with limitations,
the results suggest a gene expression approach may be
useful for defining molecular correlates of IA and HI
symptoms in ADHD phenotypes in subjects with TS. A
similar approach might be useful in ADHD phenotypes
in subjects without TS.
Additional files
Additional file 1: Table S1. ADHD symptom related genes.
Additional file 2: Table S2-1. Canonical pathways with significant over-
representation of genes that correlated with CPRS for IA, HI or both
(p<0.05, |rp| >0.4). Table S2-2. Chromosomes significantly over-enriched
with genes that correlated with CPRS IA, HI scales or both (p<0.05, |rp| >0.4).
Additional file 3: Figure S1. Co-expression analysis results of 24
common Inattention/ Hyperactivity/ Impulsivity (IA-HI) pathway-related
probesets by using two-way clustering of gene-gene correlation data.
Additional file 4: Figure S2. Co-expression analysis results of 106
Hyperactivity/ Impulsivity (HI) pathway-related probesets by using two-
way clustering of gene-gene correlation data.
Additional file 5: Figure S3. Co-expression analysis results of 48
Inattention (IA) pathway-related probesets by using two-way clustering of
gene-gene correlation data.
Additional file 6: Table S3. The multiple probesets targted to a specific
gene were highly correalted each other.
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